ArticleJournal of Korean medical science2026
Treatment Patterns and Outcomes of Anti-MuSK Antibody-Positive Myasthenia Gravis: A Retrospective Single-Center Study.
Article in Journal of Korean medical science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundThere is limited knowledge regarding the real-world treatment status of muscle-specific tyrosine kinase antibody-positive myasthenia gravis (MuSK-MG) patients in clinical practice. The aim of this study was to analyze the overall treatment patterns and outcomes of MuSK-MG in Korea.
methodsIn this single-center cohort study, we retrospectively included patients diagnosed with MuSK-MG. We analyzed their demographic features, clinical characteristics, treatment patterns focusing on corticosteroids (CSs), non-steroidal immunosuppressants (NSISs), and rituximab, and treatment outcomes. Specifically, we investigated the achievement of minimal manifestation status with a prednisolone dose 5 mg/day or below (MM-5).
resultsThe study included 30 patients with MuSK-MG, predominantly female (93.3%). The average age at time of diagnosis was 43.9 ± 16.0 years, with the onset age of 42.3 ± 16.2 years. All patients initially received CSs, and 24 patients (80%) were treated with NSISs. Tacrolimus was the most frequently prescribed NSIS, used in 70.8% of cases, followed by azathioprine (62.5%). All 10 patients who received rituximab therapy showed clinical improvement, with 5 patients (50%) achieving MM-5.
conclusionThis study summarized the treatment patterns and outcomes of patients with MuSK-MG in real-world clinical settings. As patients who received rituximab demonstrated a favorable prognosis, early administration of rituximab may be an effective treatment strategy for MuSK-MG, potentially reducing the adverse effects associated with long-term use of CSs and NSISs. Rituximab should be considered early in MuSK-MG patients who show insufficient response to initial immunosuppressive treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.